Wat is de prijs voor BioVaxys Technology Corp. (BIOV)

Het prijs van BioVaxys Technology Corp. (BIOV) is $0.05137558

Wat is de marktkapitalisatie voor BioVaxys Technology Corp. (BIOV)

Marktkapitalisatie voorBioVaxys Technology Corp. (BIOV) is $1.50M

BioVaxys Technology Corp. (BIOV) Operationele Marge

BioVaxys Technology Corp. is a clinical-stage biotechnology company specializing in the development of vaccine platforms designed to combat both viral infections and cancer. The company's pipeline includes BVX-0320, a single-strain vaccine for SARS-CoV-2, and BVX-0918A, an experimental haptenized tumor cell vaccine targeting ovarian cancer. Additionally, BioVaxys offers CoviDTH, an immunodiagnostic tool to detect immune system activity in SARS-CoV-2-exposed patients. Further initiatives encompass Papilocare, aimed at HPV-dependent cervical lesions, along with BVX-0918C for cervical cancer, the HPV viral vaccine BVX-0204, and BVX-0121, a multivalent SARS-CoV-2 vaccine. BioVaxys has established strategic collaborations, such as a bioproduction agreement with WuXi Biologics Limited to manufacture SARS-CoV-2 s-proteins crucial for BVX-0320 and CoviDTH. It also holds a research partnership with The Ohio State University, Wexner School of Medicine, focusing on BVX-0320, and has engaged Bioanalytical Systems, Inc. for preclinical toxicology evaluations of its CoviDTH immunodiagnostic. The company is headquartered in Vancouver, Canada.

Jaar	Operationele Marge	Wijzigen
Niet genoeg gegevens voor de verstrekte datums.

Jaar

Operationele Marge

Wijzigen

Niet genoeg gegevens voor de verstrekte datums.

Bedrijf	Operationele Marge	Verschil in operationele marge	Land
Vertex Pharmaceuticals Incorporated VRTX.US	38.97%	-	US
Argenx SE ARGX.US	28.81%	-	NL
Lonza Group AG LONN.SW	0.00%	-	CH
Samsung Biologics Co.,Ltd. 207940.KS	0.00%	-	KR
UCB S.A. UCB.BR	31.23%	-	BE

Bedrijf

Operationele Marge

Verschil in operationele marge

Land